

William V Padula

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7737033/publications.pdf>

Version: 2024-02-01

78
papers

2,226
citations

279798

23
h-index

243625

44
g-index

81
all docs

81
docs citations

81
times ranked

2767
citing authors

#	ARTICLE	IF	CITATIONS
1	The national cost of hospital-acquired pressure injuries in the United States. <i>International Wound Journal</i> , 2019, 16, 634-640.	2.9	320
2	Improving the Quality of Pressure Ulcer Care With Prevention. <i>Medical Care</i> , 2011, 49, 385-392.	2.4	152
3	Applying Dynamic Simulation Modeling Methods in Health Care Delivery Research—The SIMULATE Checklist: Report of the ISPOR Simulation Modeling Emerging Good Practices Task Force. <i>Value in Health</i> , 2015, 18, 5-16.	0.3	152
4	Selecting a Dynamic Simulation Modeling Method for Health Care Delivery Research—Part 2: Report of the ISPOR Dynamic Simulation Modeling Emerging Good Practices Task Force. <i>Value in Health</i> , 2015, 18, 147-160.	0.3	109
5	Societal Implications of Health Insurance Coverage for Medically Necessary Services in the U.S. Transgender Population: A Cost-Effectiveness Analysis. <i>Journal of General Internal Medicine</i> , 2016, 31, 394-401.	2.6	105
6	Implications of Coronary Artery Calcium Testing for Treatment Decisions Among Statin Candidates According to the ACC/AHA Cholesterol Management Guidelines. <i>JACC: Cardiovascular Imaging</i> , 2017, 10, 938-952.	5.3	83
7	Cost-effectiveness of Tyrosine Kinase Inhibitor Treatment Strategies for Chronic Myeloid Leukemia in Chronic Phase After Generic Entry of Imatinib in the United States. <i>Journal of the National Cancer Institute</i> , 2016, 108, djw003.	6.3	82
8	Constrained Optimization Methods in Health Services Research—An Introduction: Report 1 of the ISPOR Optimization Methods Emerging Good Practices Task Force. <i>Value in Health</i> , 2017, 20, 310-319.	0.3	79
9	Value of hospital resources for effective pressure injury prevention: a cost-effectiveness analysis. <i>BMJ Quality and Safety</i> , 2019, 28, 132-141.	3.7	77
10	Coverage for Gender-Affirming Care: Making Health Insurance Work for Transgender Americans. <i>LGBT Health</i> , 2017, 4, 244-247.	3.4	67
11	Economic value of vaccines to address the COVID-19 pandemic: a U.S. cost-effectiveness and budget impact analysis. <i>Journal of Medical Economics</i> , 2021, 24, 1060-1069.	2.1	51
12	Cost-Benefit Analysis of a Support Program for Nursing Staff. <i>Journal of Patient Safety</i> , 2020, 16, e250-e254.	1.7	44
13	Hospital-Acquired Pressure Ulcers at Academic Medical Centers in the United States, 2008–2012: Tracking Changes Since the CMS Nonpayment Policy. <i>Joint Commission Journal on Quality and Patient Safety</i> , 2015, 41, 257-263.	0.7	41
14	Why Only Test Symptomatic Patients? Consider Random Screening for COVID-19. <i>Applied Health Economics and Health Policy</i> , 2020, 18, 333-334.	2.1	40
15	Changing the cost of care for chronic myeloid leukemia: the availability of generic imatinib in the USA and the EU. <i>Annals of Hematology</i> , 2015, 94, 249-257.	1.8	39
16	Application of Constrained Optimization Methods in Health Services Research: Report 2 of the ISPOR Optimization Methods Emerging Good Practices Task Force. <i>Value in Health</i> , 2018, 21, 1019-1028.	0.3	36
17	A Framework of Quality Improvement Interventions to Implement Evidence-Based Practices for Pressure Ulcer Prevention. <i>Advances in Skin and Wound Care</i> , 2014, 27, 280-284.	1.0	35
18	Transforming Healthcare Delivery: Integrating Dynamic Simulation Modelling and Big Data in Health Economics and Outcomes Research. <i>Pharmacoeconomics</i> , 2016, 34, 115-126.	3.3	35

#	ARTICLE	IF	CITATIONS
19	Digital Health Intervention in Acute Myocardial Infarction. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2021, 14, e007741.	2.2	33
20	Adverse Effects of the Medicare PSI-90 Hospital Penalty System on Revenue-Neutral Hospital-Acquired Conditions. <i>Journal of Patient Safety</i> , 2020, 16, e97-e102.	1.7	31
21	Are Evidence-based Practices Associated With Effective Prevention of Hospital-acquired Pressure Ulcers in US Academic Medical Centers?. <i>Medical Care</i> , 2016, 54, 512-518.	2.4	27
22	Comparative Effectiveness of Quality Improvement Interventions for Pressure Ulcer Prevention in Academic Medical Centers in the United States. <i>Joint Commission Journal on Quality and Patient Safety</i> , 2015, 41, 246-AP5.	0.7	26
23	Best practices for preventing skin injury beneath personal protective equipment during the COVID-19 pandemic: A position paper from the National Pressure Injury Advisory Panel. <i>Journal of Clinical Nursing</i> , 2023, 32, 625-632.	3.0	26
24	Effectiveness and Value of Prophylactic 5-Layer Foam Sacral Dressings to Prevent Hospital-Acquired Pressure Injuries in Acute Care Hospitals. <i>Journal of Wound, Ostomy and Continence Nursing</i> , 2017, 44, 413-419.	1.0	25
25	Addressing the multisectoral impact of pressure injuries in the USA, UK and abroad. <i>BMJ Quality and Safety</i> , 2018, 27, 171-173.	3.7	24
26	Machine Learning Methods in Health Economics and Outcomes Research—The PALISADE Checklist: A Good Practices Report of an ISPOR Task Force. <i>Value in Health</i> , 2022, 25, 1063-1080.	0.3	24
27	Can Economic Model Transparency Improve Provider Interpretation of Cost-effectiveness Analysis? Evaluating Tradeoffs Presented by the Second Panel on Cost-effectiveness in Health and Medicine. <i>Medical Care</i> , 2017, 55, 909-911.	2.4	23
28	Targeting Unconscionable Prescription-Drug Prices — Maryland’s Anti-Price-Gouging Law. <i>New England Journal of Medicine</i> , 2017, 377, 101-103.	27.0	22
29	Cost-utility of colorectal cancer screening at 40 years old for average-risk patients. <i>Preventive Medicine</i> , 2020, 133, 106003.	3.4	21
30	Moral outrage in COVID-19—Understandable but not a strategy. <i>Journal of Clinical Nursing</i> , 2020, 29, 3600-3602.	3.0	20
31	Increased Adoption of Quality Improvement Interventions to Implement Evidence-Based Practices for Pressure Ulcer Prevention in U.S. Academic Medical Centers. <i>Worldviews on Evidence-Based Nursing</i> , 2015, 12, 328-336.	2.9	19
32	Health Care Costs and Cost-effectiveness in Laryngotracheal Stenosis. <i>Otolaryngology - Head and Neck Surgery</i> , 2019, 160, 679-686.	1.9	19
33	Using clinical data to predict high-cost performance coding issues associated with pressure ulcers: a multilevel cohort model. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2017, 24, e95-e102.	4.4	18
34	Staphylococcus Aureus Prevention Strategies in Cardiac Surgery: A Cost-Effectiveness Analysis. <i>Annals of Thoracic Surgery</i> , 2018, 105, 47-53.	1.3	18
35	The cost-effectiveness of sub-epidermal moisture scanning to assess pressure injury risk in U.S. health systems. <i>Journal of Patient Safety and Risk Management</i> , 2020, 25, 147-155.	0.6	17
36	Building information for systematic improvement of the prevention of hospital-acquired pressure ulcers with statistical process control charts and regression. <i>BMJ Quality and Safety</i> , 2012, 21, 473-480.	3.7	16

#	ARTICLE	IF	CITATIONS
37	Measuring patient experiences on hospitalist and teaching services: Patient responses to a 30-day postdischarge questionnaire. <i>Journal of Hospital Medicine</i> , 2016, 11, 99-104.	1.4	16
38	Patterns of Hospital Performance on the Hospital-Wide 30-Day Readmission Metric: Is the Playing Field Level?. <i>Journal of General Internal Medicine</i> , 2018, 33, 57-64.	2.6	16
39	The Standardized Pressure Injury Prevention Protocol for improving nursing compliance with best practice guidelines. <i>Journal of Clinical Nursing</i> , 2019, 28, 367-371.	3.0	16
40	Supply chain failures amid Covid-19 signal a new pillar for global health preparedness. <i>Journal of Clinical Nursing</i> , 2021, 30, e1-e3.	3.0	16
41	Market Exclusivity for Drugs with Multiple Orphan Approvals (1983-2017) and Associated Budget Impact in the US. <i>Pharmacoeconomics</i> , 2020, 38, 1115-1121.	3.3	15
42	Factors Influencing Adoption of Hospital-Acquired Pressure Ulcer Prevention Programs in US Academic Medical Centers. <i>Journal of Wound, Ostomy and Continence Nursing</i> , 2015, 42, 327-330.	1.0	14
43	Cost-effectiveness of Pneumococcal Vaccination Among Patients With CKD in the United States. <i>American Journal of Kidney Diseases</i> , 2019, 74, 23-35.	1.9	13
44	Cost-effectiveness of a Digital Health Intervention for Acute Myocardial Infarction Recovery. <i>Medical Care</i> , 2021, 59, 1023-1030.	2.4	13
45	Preoperative paravertebral blocks for the management of acute pain following mastectomy: a cost-effectiveness analysis. <i>Breast Cancer Research and Treatment</i> , 2017, 165, 477-484.	2.5	12
46	Thoracic Oncology Multidisciplinary Clinic Reduces Unnecessary Health Care Expenditure Used in the Workup of Patients With Non-small-cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2019, 20, e430-e441.	2.6	12
47	Is the Choice of Cost-Effectiveness Threshold in Cost-Utility Analysis Endogenous to the Resulting Value of Technology? A Systematic Review. <i>Applied Health Economics and Health Policy</i> , 2021, 19, 155-162.	2.1	12
48	Five-layer border dressings as part of a quality improvement bundle to prevent pressure injuries in US skilled nursing facilities and Australian nursing homes: A cost-effectiveness analysis. <i>International Wound Journal</i> , 2019, 16, 1263-1272.	2.9	11
49	Cost-effectiveness of multi-layered silicone foam dressings for prevention of sacral and heel pressure ulcers in high-risk intensive care unit patients: An economic analysis of a randomised controlled trial. <i>International Wound Journal</i> , 2020, 17, 1291-1299.	2.9	10
50	Ideas About Resourcing Health Care in the United States: Can Economic Evaluation Achieve Meaningful Use?. <i>Annals of Internal Medicine</i> , 2021, 174, 80-85.	3.9	9
51	Complexity Bias in the Prevention of Iatrogenic Injury. <i>Mayo Clinic Proceedings</i> , 2022, 97, 221-224.	3.0	8
52	An Approach to Acquiring, Normalizing, and Managing EHR Data From a Clinical Data Repository for Studying Pressure Ulcer Outcomes. <i>Journal of Wound, Ostomy and Continence Nursing</i> , 2016, 43, 39-45.	1.0	7
53	Improvements in Hospital Adverse Event Rates. <i>JAMA - Journal of the American Medical Association</i> , 2022, 328, 148.	7.4	7
54	Individualized cost-effectiveness analysis of patient-centered care: a case series of hospitalized patient preferences departing from practice-based guidelines. <i>Journal of Medical Economics</i> , 2017, 20, 288-296.	2.1	6

#	ARTICLE	IF	CITATIONS
55	Care Management to Reduce Disparities and Control Hypertension in Primary Care. <i>Medical Care</i> , 2018, 56, 179-185.	2.4	6
56	Cost-Effectiveness of Craniotomy for Epidural Hematomas at a Major Government Hospital in Cambodia. <i>World Journal of Surgery</i> , 2017, 41, 2215-2223.	1.6	5
57	Allocating provider resources to diagnose and treat restless legs syndrome: a cost-utility analysis. <i>Sleep Medicine</i> , 2017, 38, 44-49.	1.6	4
58	Cost Benefit of Comprehensive Primary and Preventive School-Based Health Care. <i>American Journal of Preventive Medicine</i> , 2018, 54, 80-86.	3.0	4
59	VALUE AND PERFORMANCE OF ACCOUNTABLE CARE ORGANIZATIONS: A COST-MINIMIZATION ANALYSIS. <i>International Journal of Technology Assessment in Health Care</i> , 2018, 34, 388-392.	0.5	4
60	Unintended consequences of quality improvement programs on the prevention of hospital-acquired conditions: Avoiding the temptation to bite into low-hanging fruit. <i>Journal of Patient Safety and Risk Management</i> , 2018, 23, 123-127.	0.6	4
61	Finding Resolution for the Responsible Transparency of Economic Models in Health and Medicine. <i>Medical Care</i> , 2017, 55, 915-917.	2.4	3
62	Expanding the Role of the Patient-Centered Outcomes Research Institute: Reauthorization and Facilitating Value Assessments. <i>Applied Health Economics and Health Policy</i> , 2019, 17, 757-759.	2.1	3
63	Characteristics associated with time-to-treatment initiation for chronic Hepatitis C with new direct acting antivirals. <i>Pharmacoepidemiology and Drug Safety</i> , 2021, 30, 86-96.	1.9	3
64	Cost-effectiveness of total state coverage for hepatitis C medications. <i>American Journal of Managed Care</i> , 2021, 27, e171-e177.	1.1	3
65	Paying for Drugs After the Medicare Part D Beneficiary Reaches the Catastrophic Limit: Lessons on Cost Sharing from Other US Policy Partnerships Between Government and Commercial Industry. <i>Applied Health Economics and Health Policy</i> , 2018, 16, 753-763.	2.1	2
66	Cost-Effectiveness Analysis of Single-Use EEG Cup Electrodes Compared with Reusable EEG Cup Electrodes. <i>PharmacoEconomics - Open</i> , 2019, 3, 265-272.	1.8	2
67	Discontinuation and nonpublication of interventional clinical trials conducted in ophthalmology. <i>Canadian Journal of Ophthalmology</i> , 2020, 55, 71-75.	0.7	2
68	Cost-effectiveness Analysis of Screening Extremely Low Birth Weight Children for Hepatoblastoma Using Serum Alpha-fetoprotein. <i>Journal of Pediatrics</i> , 2020, 225, 80-89.e4.	1.8	2
69	Impact of Adding Pharmacists and Comprehensive Medication Management to a Medical Group's Transition of Care Services. <i>Medical Care</i> , 2021, 59, 519-527.	2.4	2
70	Global digital social learning as a strategy to promote engagement in the era of COVID-19. <i>Journal of Clinical Nursing</i> , 2021, 30, 2366-2372.	3.0	2
71	Wound, Ostomy, and Continence Nurses Could Be an Answer to the Economic Impact of Coronavirus. <i>Journal of Wound, Ostomy and Continence Nursing</i> , 2020, 47, 523-524.	1.0	1
72	What current and missing data can teach us about medication errors. <i>BMJ Quality and Safety</i> , 2021, 30, 89-91.	3.7	1

#	ARTICLE	IF	CITATIONS
73	The cost-effectiveness of therapeutic drug monitoring for the prescription drug-based treatment of chronic myeloid leukemia. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2021, 27, 1077-1085.	0.9	1
74	A Call for Open-Source Cost-Effectiveness Analysis. <i>Annals of Internal Medicine</i> , 2018, 168, 528.	3.9	1
75	Value of Triage Treatment Strategies to Distribute Hepatitis C Direct-Acting Antiviral Agents in an Integrated Healthcare System: A Cost-Effectiveness Analysis. <i>Value in Health</i> , 2022, , .	0.3	1
76	Reply to Comment on "Market Exclusivity for Drugs with Multiple Orphan Approvals (1983-2017) and Associated Budget Impact in the US". <i>Pharmacoeconomics</i> , 2020, 38, 1375-1376.	3.3	0
77	Valuing Cures: Not If, But When?. <i>Value in Health</i> , 2021, 24, 753-754.	0.3	0
78	Impact of Neighborhood Social and Environmental Resources on Medicaid Spending. <i>American Journal of Preventive Medicine</i> , 2021, 61, e93-e101.	3.0	0